1. Taiwan Stocks

  2. •

    Health technology

  3. •

    Biotechnology
TaiMed Biologics Inc.

TaiMed Biologics Inc.

TTPEX:4147
61.10
TWD
-1.40
(-2.24%)
-0.51EPS
17.60BMarket Cap
Nov 18Next Earn
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
- -
- -
- -
0.01
0.03
0.95
2.76
2.82
1.62
2.2
1.95
2.27
2.24
2.26
Basic EPS, GAAP
-1.28
-1.2
-2.13
-1.12
-2.07
-1.26
-2.26
-0.72
-1.84
-1.05
-0.77
-0.75
-0.61
-0.51
Free Cash Flow per Basic Share
-0.85
-0.97
-2.03
-0.72
-3.15
-6.71
-3.1
-2.29
-0.88
-2.38
-0.13
-1.49
0.62
0.39
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
3.34
8.33
19.53
18.59
16.9
16
14.02
13.35
11.49
10.6
10
14.73
14.12
13.58
Tangible Book Value per Share
1.64
6.81
18.2
17.26
15.52
13.48
11.13
9.68
8.28
7.77
7.56
12.76
12.5
12.13
Basic Weighted Avg Shares
197
235
221
252
254
254
256
256
256
256
253
268
273
274
Sales/Revenue/Turnover
- -
- -
- -
2
8
241
705
722
413
563
492
610
611
619
Operating Margin (%)
- -
- -
- -
-15,072.16
-6,462.97
-133.08
-55.36
-18.38
-117.64
-34.08
-33.8
-41.34
-31.84
-30.27
Depreciation Expense
23
23
3
3
4
63
93
140
157
156
155
154
154
154
Net Income, GAAP
-252
-282
-472
-282
-525
-322
-579
-183
-471
-269
-195
-202
-168
-139
Effective Tax Rate (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Profit Margin (%)
- -
- -
- -
-13,581.98
-6,218.04
-133.47
-82.14
-25.37
-113.91
-47.83
-39.61
-33.08
-27.44
-22.42
Working Capital
317
1,480
4,549
4,373
3,560
2,283
2,029
2,316
2,110
1,835
1,790
3,259
3,069
2,861
LT Debt
- -
- -
- -
- -
- -
- -
32
567
565
550
522
493
463
448
Total Equity
658
1,830
4,900
4,714
4,292
4,080
3,586
3,416
2,942
2,715
2,566
4,023
3,858
3,676
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)
-32.65
-22.65
-14.02
-5.87
-11.65
-7.68
-15.09
-5.24
-14.82
-9.52
-7.38
-6.13
-4.26
-3.66

Capital Structure

TWD

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
30
30
30
LT Borrowings
440
433
426
LT Finance Leases
23
22
22
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
273
272
271
Market Capitalization
16,720
13,939
17,596

Working Capital

TWD

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
3,322
3,179
3,058
Cash, Cash Equivalents & STI
1,771
1,637
1,607
Accounts Receivable, Net
65
74
32
Inventories
828
810
743
Total Current Liabilities
254
189
198
Payables & Accruals
- -
- -
- -
ST Debt
30
30
30
Deferred Revenue
- -
- -
- -

Growth Rates

TWD

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
-0.89%
5.12%
-4.11%
Free Cash Flow
134.18%
205.78%
-142.21%
Net Income, GAAP
9.19%
14.63%
-16.87%
Sales/Revenue/Turnover
- -
1%
0.19%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

TWD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
179
147
139
146
610
2025
176
138
148
150
611
2026
166
156
- -
- -
- -

Quarterly Earnings Per Share

TWD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
-0.06
-0.1
-0.14
-0.45
-0.75
2025
-0.09
-0.22
-0.05
-0.25
-0.61
2026
0.06
-0.27
- -
- -
- -

Quarterly Dividends Per Share

TWD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -

Company Description

Company Profile APIChatGPT
CEO
Chin-Ming Chang
Full Time Employees
799
Sector
Health technology
Industry
Biotechnology
Address
NO. 607, Ruiguang Rd. Taipei TP Taiwan 11492
IPO Date
Jun 28, 2010
Website
taimedbiologics.com
Similar Companies
Moderna, Inc. (NASDAQ:MRNA)
Amgen Inc. (NASDAQ:AMGN)
Iovance Biotherapeutics, Inc. (NASDAQ:IOVA)
Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX)
Novavax, Inc. (NASDAQ:NVAX)
10x Genomics, Inc. (NASDAQ:TXG)
Business
TaiMed Biologics Inc. operates as a specialized biotechnology firm, focusing on the research, development, production, and commercialization of novel pharmaceutical agents for addressing and preventing infectious diseases. The company offers Trogarzo (ibalizumab, TMB-355), a humanized monoclonal antibody, approved in the United States and other regions for individuals living with multidrug-resistant HIV-1 infection, available as both intravenous infusion and IV push formulations. Beyond its marketed product, TaiMed is actively advancing a pipeline of investigational therapies. This includes the long-acting TMB-365 and TMB-380 combination, a dual monoclonal antibody treatment for HIV, which recently completed its Phase 2a clinical study with positive topline results and is poised to enter Phase 2b in 2025, having received U.S. FDA Fast Track designation. The company is also exploring antibody-drug conjugates (ADCs) for potential applications in cancer and precision HIV/autoimmune therapies. Established in 2007 and based in Taipei, Taiwan, TaiMed Biologics additionally provides contract development and manufacturing (CDMO) services for biologics.